Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
<b>Background</b>: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette–Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/156 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588964325752832 |
|---|---|
| author | Inmaculada Ruiz-Lorente Lourdes Gimeno Alicia López-Abad Pedro López Cubillana Tomás Fernández Aparicio Lucas Jesús Asensio Egea Juan Moreno Avilés Gloria Doñate Iñiguez Pablo Luis Guzmán Martínez-Valls Gerardo Server Belén Ferri José Antonio Campillo María Victoria Martínez-Sánchez Alfredo Minguela |
| author_facet | Inmaculada Ruiz-Lorente Lourdes Gimeno Alicia López-Abad Pedro López Cubillana Tomás Fernández Aparicio Lucas Jesús Asensio Egea Juan Moreno Avilés Gloria Doñate Iñiguez Pablo Luis Guzmán Martínez-Valls Gerardo Server Belén Ferri José Antonio Campillo María Victoria Martínez-Sánchez Alfredo Minguela |
| author_sort | Inmaculada Ruiz-Lorente |
| collection | DOAJ |
| description | <b>Background</b>: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette–Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/HLA-E interactions. Biomarkers are necessary to optimize the use of these therapies. <b>Methods</b>: We evaluated killer-cell immunoglobulin-like receptors (KIRs) and HLA-I genotyping and the expression of NK cell receptors in circulating T and NK lymphocytes at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 treated with other therapies), as well as in 648 patients with other cancers and 973 healthy donors as controls. The proliferation and production of cytokines and cytotoxicity were evaluated in peripheral blood mononuclear cells, stimulated in vitro with anti-CD3/CD28 or BCG, from selected patients based on HLA-B −21M/T dimorphism (NKG2A ligands). <b>Results</b>: The HLA-B −21M/T genotype showed opposing results in BC patients treated with BCG or other therapies. The MM genotype, compared to MT and TT, was associated with a longer 75th-percentile overall survival (not reached vs. 68.0 ± 13.7 and 52.0 ± 8.3 months, <i>p</i> = 0.034) in BCG, but a shorter (8.0 ± 2.4 vs. 21.0 ± 3.4 and 19.0 ± 4.9 months, <i>p</i> = 0.131) survival in other treatments. The HLA-B −21M/T genotype was an independent predictive parameter of the progression-free survival (HR = 2.08, <i>p</i> = 0.01) and the OS (HR = 2.059, <i>p</i> = 0.039) of BC patients treated with BCG, together with age and tumor histopathologic characteristics. The MM genotype was associated with higher counts of circulating CD56<sup>bright</sup>, fewer KIR2DL1/L2<sup>+</sup> NK cells, and lower NKG2A expression, but not with differential in vitro NK cell functionality. <b>Conclusions</b>: The HLA-B −21M/T is independently associated with BC patient outcomes and can help to optimize the use of new immunotherapies in these patients. |
| format | Article |
| id | doaj-art-3bf8ac17041b4f94899ad09d9cd2938a |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-3bf8ac17041b4f94899ad09d9cd2938a2025-01-24T13:24:12ZengMDPI AGBiomedicines2227-90592025-01-0113115610.3390/biomedicines13010156Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other TherapiesInmaculada Ruiz-Lorente0Lourdes Gimeno1Alicia López-Abad2Pedro López Cubillana3Tomás Fernández Aparicio4Lucas Jesús Asensio Egea5Juan Moreno Avilés6Gloria Doñate Iñiguez7Pablo Luis Guzmán Martínez-Valls8Gerardo Server9Belén Ferri10José Antonio Campillo11María Victoria Martínez-Sánchez12Alfredo Minguela13Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainUrology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainUrology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainUrology Service, Morales Meseguer Hospital, 30008 Murcia, SpainUrology Service, De la Vega Lorenzo Guirao Hospital, 30530 Murcia, SpainUrology Service, Santa Lucia Hospital, 30202 Murcia, SpainUrology Service, Los Arcos Hospital, 30739 Murcia, SpainUrology Service, Reina Sofía Hospital, 30003 Murcia, SpainUrology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainPathology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain<b>Background</b>: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette–Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/HLA-E interactions. Biomarkers are necessary to optimize the use of these therapies. <b>Methods</b>: We evaluated killer-cell immunoglobulin-like receptors (KIRs) and HLA-I genotyping and the expression of NK cell receptors in circulating T and NK lymphocytes at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 treated with other therapies), as well as in 648 patients with other cancers and 973 healthy donors as controls. The proliferation and production of cytokines and cytotoxicity were evaluated in peripheral blood mononuclear cells, stimulated in vitro with anti-CD3/CD28 or BCG, from selected patients based on HLA-B −21M/T dimorphism (NKG2A ligands). <b>Results</b>: The HLA-B −21M/T genotype showed opposing results in BC patients treated with BCG or other therapies. The MM genotype, compared to MT and TT, was associated with a longer 75th-percentile overall survival (not reached vs. 68.0 ± 13.7 and 52.0 ± 8.3 months, <i>p</i> = 0.034) in BCG, but a shorter (8.0 ± 2.4 vs. 21.0 ± 3.4 and 19.0 ± 4.9 months, <i>p</i> = 0.131) survival in other treatments. The HLA-B −21M/T genotype was an independent predictive parameter of the progression-free survival (HR = 2.08, <i>p</i> = 0.01) and the OS (HR = 2.059, <i>p</i> = 0.039) of BC patients treated with BCG, together with age and tumor histopathologic characteristics. The MM genotype was associated with higher counts of circulating CD56<sup>bright</sup>, fewer KIR2DL1/L2<sup>+</sup> NK cells, and lower NKG2A expression, but not with differential in vitro NK cell functionality. <b>Conclusions</b>: The HLA-B −21M/T is independently associated with BC patient outcomes and can help to optimize the use of new immunotherapies in these patients.https://www.mdpi.com/2227-9059/13/1/156bladder cancerimmunotherapyBCGNK cellsNKG2AHLA-E |
| spellingShingle | Inmaculada Ruiz-Lorente Lourdes Gimeno Alicia López-Abad Pedro López Cubillana Tomás Fernández Aparicio Lucas Jesús Asensio Egea Juan Moreno Avilés Gloria Doñate Iñiguez Pablo Luis Guzmán Martínez-Valls Gerardo Server Belén Ferri José Antonio Campillo María Victoria Martínez-Sánchez Alfredo Minguela Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies Biomedicines bladder cancer immunotherapy BCG NK cells NKG2A HLA-E |
| title | Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies |
| title_full | Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies |
| title_fullStr | Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies |
| title_full_unstemmed | Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies |
| title_short | Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies |
| title_sort | differential role of nkg2a hla e interaction in the outcomes of bladder cancer patients treated with i m bovis i bcg or other therapies |
| topic | bladder cancer immunotherapy BCG NK cells NKG2A HLA-E |
| url | https://www.mdpi.com/2227-9059/13/1/156 |
| work_keys_str_mv | AT inmaculadaruizlorente differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT lourdesgimeno differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT alicialopezabad differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT pedrolopezcubillana differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT tomasfernandezaparicio differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT lucasjesusasensioegea differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT juanmorenoaviles differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT gloriadonateiniguez differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT pabloluisguzmanmartinezvalls differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT gerardoserver differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT belenferri differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT joseantoniocampillo differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT mariavictoriamartinezsanchez differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies AT alfredominguela differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies |